Class I–restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8+ T Cells by Kurts, Christian et al.
 
239
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/07/239/07 $2.00
Volume 186, Number 2, July 21, 1997 239–245
 
Class I–restricted Cross-Presentation of Exogenous
Self-Antigens Leads to Deletion of Autoreactive
 
CD8
 
1
 
 T Cells
 
By Christian Kurts,
 
*
 
 Hiroshi Kosaka,
 
*
 
 Francis R. Carbone,
 
‡
 
Jacques F.A.P. Miller,
 
*
 
 and William R. Heath
 
*
 
From the 
 
*
 
Thymus Biology Unit, The Walter and Eliza Hall Institute of Medical Research, Royal 
Melbourne Hospital, Parkville 3050, Victoria, Australia; and the 
 
‡
 
Monash Medical School, Alfred 
Hospital, Prahran 3181, Victoria, Australia
 
Summary
 
In this report, we show that cross-presentation of self-antigens can lead to the peripheral dele-
tion of autoreactive CD8
 
1
 
 T cells. We had previously shown that transfer of ovalbumin
(OVA)-specific CD8
 
1
 
 T cells (OT-I cells) into rat insulin promoter–membrane-bound form of
OVA transgenic mice, which express the model autoantigen OVA in the proximal tubular cells
of the kidneys, the 
 
b
 
 cells of the pancreas, the thymus, and the testis of male mice, led to the ac-
tivation of OT-I cells in the draining lymph nodes. This was due to class I–restricted cross-pre-
sentation of exogenous OVA on a bone marrow–derived antigen presenting cell (APC) popu-
lation. Here, we show that adoptively transferred or thymically derived OT-I cells activated by
cross-presentation are deleted from the peripheral pool of recirculating lymphocytes. Such de-
letion only required antigen recognition on a bone marrow–derived population, suggesting
that cells of the professional APC class may be tolerogenic under these circumstances. Our re-
sults provide a mechanism by which the immune system can induce CD8
 
1
 
 T cell tolerance to
autoantigens that are expressed outside the recirculation pathway of naive T cells.
 
S
 
everal mechanisms play a role in tolerance induction to
extra thymic self-antigens. For class I–restricted CD8
 
1
 
T cells, ignorance, anergy, and deletion can operate to ren-
der an animal tolerant to antigen expressed in peripheral
tissues (1–14). However, the current dogma provides an in-
teresting dilemma with regard to our understanding of how
tolerance is achieved. Anergy and deletion both require in-
teraction of T cells with the self-antigen, and naive T cells
are thought not to recirculate through nonlymphoid tissue
(15). Thus, those CD8
 
1
 
 T cells specific for antigens ex-
pressed only in nonlymphoid tissues, e.g., in the 
 
b
 
 cells of
the pancreas, should not be susceptible to these forms of
tolerance. This leaves ignorance as the only mechanism for
avoiding autoimmunity to such antigens, a somewhat un-
satisfactory situation because activated CD8
 
1
 
 T cells have
wider recirculation pathways than naive cells (15), and can
potentially cause autoimmune damage in tissues previously
ignored (3, 4, 10). Consequently, we might expect autoim-
munity to be more prevalent, or that additional tolerogenic
mechanisms exist.
To date, many studies examining peripheral tolerance of
CD8
 
1
 
 T cells have used MHC molecules as their model
autoantigens (5–10, 14, 16). These molecules are seen only
in an unprocessed form, and therefore only on those cells
that themselves express the autoantigen. Although such
studies have contributed to our understanding of the fate of
autoreactive CD8
 
1
 
 T cells, they have not allowed for the
possible effects of processing and presentation of tissue anti-
gens by professional APCs.
Peptide antigens presented by MHC class I molecules are
generally thought to be derived from intracellularly synthe-
sized proteins (17–19). However, exogenous antigens can
also be presented by class I MHC molecules under certain
circumstances (20–26) and the induction of CTL via this
exogenous pathway for class I–restricted presentation has
been referred to as cross-priming. We have recently shown
that such presentation, when applied to self-antigens, can lead
to the activation of autoreactive CD8
 
1
 
 T cells (27). These
studies used the rat insulin promoter (RIP)
 
1
 
–mOVA trans-
genic mouse model, where a membrane-bound form of
ovalbumin (mOVA) was expressed by pancreatic 
 
b
 
 cells, kid-
ney proximal tubular cells, the thymus, and in the testis of
male mice. Transgenic OVA-specific CD8
 
1
 
 T cells (OT-I
cells) adoptively transferred into RIP–mOVA mice were
activated in the lymph nodes draining OVA-expressing tis-
sues. This activation was due to class I–restricted presentation
of exogenously derived OVA on a bone marrow–derived
APC population. Here, we investigate the fate of autoreac-
 
1
 
Abbreviations used in this paper:
 
 HA, hemagglutinin; mOVA, membrane-
bound form of ovalbumin; OT-I, OVA-specific CD8
 
1
 
 T cells; RIP, rat
insulin promoter; TG, thymus grafted.
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tive CD8
 
1
 
 T cells activated by this cross-presentation path-
way and provide evidence that these cells are deleted.
 
Materials and Methods
 
Mice.
 
All mice were bred and maintained at the Walter and
Eliza Hall Institute of Medical Research. For all experiments, fe-
male mice between 8 and 16 wk of age were used. RIP–mOVA
and OT-I transgenic mice were generated and screened as previ-
ously described (27, 28).
 
Adult Thymectomized, Thymus-grafted, Bone Marrow Chimeras.
 
Adult thymectomized, thymus-grafted, bone marrow chimeric RIP-
mOVA mice (TG-RIP mice) and nontransgenic mice (TG-non-
transgenic mice) were generated as described (9, 14). In brief, 2–6
wk after adult thymectomy RIP–mOVA mice and their nontrans-
genic littermates were lethally irradiated with 900 cGy and recon-
stituted with T cell–depleted bone marrow from OT-I mice. The
next day, radioresistant T cells were depleted with 100 
 
m
 
l of T24
(anti-Thy-1) ascites intraperitoneally. 1–2 wk after irradiation, mice
were grafted with a sex-matched 1,500 cGy irradiated thymus
graft from a nontransgenic newborn B6 mouse under the kidney
capsule. This approach ensured that OT-I cells were not deleted
intrathymically due to aberrant expression of OVA in this tissue.
 
Preparation of OT-I Cells for Adoptive Transfer.
 
OT-I RAG-1
 
2
 
/
 
2
 
cells were prepared from LN and spleens of transgenic mice as de-
scribed (27). In brief, erythrocytes and macrophages were re-
moved by treatment with the anti-heat stable antigen mAb J11d
and complement. OT-I cells from RAG-1
 
2
 
/
 
2
 
 mice were of a na-
ive phenotype (CD44
 
lo
 
, CD69
 
2
 
, IL-2R
 
2
 
). 0.25–6 
 
3
 
 10
 
6
 
 cells
were injected intravenously into recipient mice.
 
5,6-Carboxy-Succinimidyl-Fluoresceine-Ester Labeling of OT-I
Cells.
 
5,6-carboxy-succinimidyl-fluoresceine-ester (CFSE) la-
beling was performed as previously described (29–31). OT-I cells
were resuspended in PBS containing 0.1% BSA (Sigma Chem.
Co., St. Louis, MO) at 10 
 
3
 
 10
 
6
 
 cells/ml. For fluorescence label-
ing, 2 
 
m
 
l of a CFSE (Molecular Probes, Eugene, Oregon) stock
solution (5 mM in DMSO) were incubated with 10 
 
3
 
 10
 
6
 
 cells
for 10 min at 37
 
8
 
C.
 
FACS
 
Ò
 
 Analysis.
 
LN or spleen cells were stained for three-
color FACS
 
Ò
 
 analysis as described (10), using the following mAbs:
PE-conjugated anti-CD8 (YTS 169.4) was from Caltag (San Fran-
cisco, CA). Biotinylated anti-CD69 (H1.SF3) and PE-labeled anti–
L-selectin (Mel-14) were from PharMingen (San Diego, CA). Anti-
V
 
a
 
2 TCR (B20.1) and anti-V
 
b
 
5.1/2 TCR (MR9-4) mAbs (27)
were conjugated to biotin or to FITC. Biotin-labeled Abs were
detected with Streptavidin (SAVP)–Tricolor (Caltag). Analysis was
performed on a FACScan
 
Ò
 
 using Lysis II software. Live gates
were set on lymphocytes by forward and side scatter profiles.
10,000–20,000 live cells were collected for analysis. OT-I donor
cells in the LNs from recipient mice were identified by staining
for V
 
a
 
2
 
1
 
 V
 
b
 
5
 
1
 
 CD8
 
1
 
 cells.
For analysis of fluorescent labeled cells, 50,000 CD8
 
1
 
 cells were
collected and analyzed using WEASEL software (F. Battye, Wal-
ter and Eliza Hall Institute, Melbourne, Australia).
 
Histology.
 
Tissues were fixed in Bouin’s solution and paraffin
sections were stained with hematoxylin and eosin using standard
methods.
 
Results
 
Activation of OVA-specific CD8
 
1
 
 T Cells by Cross-presenta-
tion in RIP–mOVA Mice.
 
RIP–mOVA mice express a mem-
brane-bound form of OVA in the 
 
b
 
 cells of the pancreas,
the proximal tubular cells of the kidney, the thymus, and in
the testis of male mice (27). When OVA-specific CD8
 
1
 
 T
cells from the OT-I transgenic line (OT-I cells) were trans-
ferred into RIP–mOVA mice, they were activated in the
draining lymph nodes of OVA-expressing tissues (27). In
this report, we have used a novel and more sensitive
method for the identification of proliferating cells in vivo
(29–31). OT-I cells were labeled with the fluorescent dye
CFSE and then transferred into RIP–mOVA mice. When
CFSE-labeled cells divide, the two daughter cells receive
approximately half of the original fluorescence, and their
progeny a quarter, and so on. Thus, a cell that has divided 
 
n
 
times will exhibit a 2
 
n
 
-fold reduced fluorescence intensity.
Therefore, on a FACS
 
Ò
 
 histogram, separate peaks appear
for cells that have divided 1–8 times. After nine cell cycles,
the fluorescent dye is diluted to background intensity. Fig.
1 shows the CFSE profiles of 5 
 
3
 
 10
 
6
 
 OT-I cells trans-
ferred into RIP–mOVA mice 43 h earlier. Multiple peaks
are seen only in the renal (Fig. 1 
 
A
 
) and pancreatic (Fig. 1
 
B
 
) lymph nodes, confirming that OT-I cells were activated
and proliferated only in these sites.
Using the above technique, divided cells were first ap-
parent at 25 h after transfer (data not shown). After 43 h,
some OT-I cells had divided four times (Fig. 1), six times
within 52 h (data not shown), greater than eight times
Figure 1. Proliferation of OT-I cells in lymph nodes draining OVA-
expressing tissues of RIP–mOVA mice. 5 3 106 CFSE-labeled OT-I cells
were injected intravenously into RIP–mOVA mice and nontransgenic
littermates. 43 h later, lymphocytes prepared from the renal (A), pancre-
atic (B), and inguinal (C) LN of RIP–mOVA mice, and from the renal
LN of nontransgenic recipients were analyzed by flow cytometry. Profiles
were gated on CD81 cells. 
241
 
Kurts et al.
 
within 68 h (Fig. 2). Therefore, one cell cycle required
 
z
 
4.5 h in vivo.
These results indicate that OT-I cells were able to re-
spond to antigen presented in the lymph nodes that drained
OVA-expressing tissues. Previously, we showed that in the
absence of a bone marrow–derived APC capable of pre-
senting OVA to OT-I cells, no proliferation was observed
(27). To determine whether OVA presentation by such
bone marrow–derived APCs alone was sufficient to induce
OT-I cell proliferation, we took advantage of bm1 mice,
which express a mutation in the K
 
b
 
 molecule such that
K
 
bm1
 
 cannot present OVA to OT-I cells (32). RIP–mOVA
mice, which were crossed onto the bm1 haplotype (RIP–
mOVA.bm1), were lethally irradiated and reconstituted with
B6 bone marrow (B6
 
®
 
RIP–mOVA.bm1). In these chi-
meric mice, K
 
b
 
 is expressed by bone marrow–derived cells
but not by peripheral tissue cells such as islet 
 
b
 
 cells or kid-
ney proximal tubular cells. 5 
 
3
 
 10
 
6
 
 CFSE-labeled OT-I
cells were adoptively transferred into the chimeric RIP–
mOVA mice and, 3 d later, lymphoid tissues were analyzed
by flow cytometry (Fig. 2). Proliferation of OT-I cells was
observed in the renal (Fig. 2 
 
C
 
) and pancreatic (data not
shown) nodes, but not in the inguinal lymph nodes of
B6
 
®
 
RIP–mOVA.bm1 chimeras (Fig. 2 
 
G
 
). This result
showed that antigen presentation by bone marrow–derived
cells was sufficient to induce proliferation of OT-I cells.
The proliferation was not as intense as in normal RIP–
mOVA mice (see Fig. 1), but was comparable to that seen
in B6
 
®
 
RIP–mOVA.B6 control chimeras that were en-
tirely of the B6 haplotype (Fig. 2, 
 
A
 
 and 
 
E
 
). This implied
that the less vigorous response seen in chimeric mice may
be the result of irradiation. As previously reported (27),
OT-I cells were not activated when the bone marrow com-
partment was of the bm1 haplotype (bm1
 
®
 
RIP–mOVA.B6
or bm1
 
®
 
mOVA.bm1), indicating that antigen presenta-
tion by a bone marrow–derived cell was not only sufficient,
but also essential for OT-I activation.
 
Deletion of Adoptively Transferred OT-I Cells in the Periph-
ery of RIP–mOVA Mice.
 
The above results indicate that a
bone marrow–derived APC was capable of processing and
presenting antigens expressed by peripheral tissues for acti-
vation of autoreactive CD8
 
1
 
 T cells. To determine how
the immune system normally copes with such autoreactive
cells, we examined the ultimate fate of these cells. To de-
tect adoptively transferred OT-I cells in unirradiated recip-
ients several weeks after transfer, it was necessary to inject
at least 5 
 
3
 
 10
 
6
 
 cells. However, under these circumstances
OT-I cells infiltrated the pancreatic islets after day 3, and
caused diabetes in 100% of 16 RIP–mOVA mice by day 9
(data not shown). Smaller numbers of cells, e.g., 0.25 
 
3
 
10
 
6
 
 cells, did not cause diabetes in 25 recipients, but detec-
tion of these few cells was not possible several weeks after
transfer, even in nontransgenic controls. Presumably, OT-I
cells were activated after transfer in both cases, but only the
larger dose caused sufficient destruction to result in diabe-
tes. To avoid the problem of 
 
b
 
 cell destruction, we trans-
ferred 6 
 
3
 
 10
 
6
 
 OT-I cells into B6
 
®
 
RIP–mOVA.bm1 chi-
meric mice, in which OT-I cells could recognize antigen
on the cross-presenting bone marrow–derived APCs, but
could not interact with OVA-expressing peripheral tissues
of the bm1 haplotype. After 8 wk, far fewer OT-I cells
Figure 2. Bone marrow–derived APC activate OT-I cells in the drain-
ing LN of RIP–mOVA mice. 5 3 106 CFSE labeled OT-I cells were
transferred into RIP–mOVA mice backcrossed to B6 (A, B, E, F) or bm1
(C, D, G, H) and grafted with B6 (A, C, E, G) or bm1 (B, D, F, H) bone
marrow. After 3 d, renal (A–D) and inguinal (E–H) lymph node cells
were examined by flow cytometry. Profiles were gated for CD81 cells.
Figure 3. OT-I cells are deleted in response to recognition of antigen
on cross-presenting APC. Bone marrow from B6 mice was grafted into
RIP–mOVA.bm1 mice and nontransgenic littermates. 14 wk later, 6 3
106 OT-I cells were adoptively transferred, and after 8 wk the number of
Va21Vb51CD81 cells in the LN and spleen of the recipients was deter-
mined by flow cytometry. The proportion of Va21Vb51 cells in the
CD81 population was 7.5–10% in nontransgenic, and 1.4–3.5% in trans-
genic recipients. An average of 1.4% of CD81 cells were Va21Vb51 in
uninjected mice. To derive the total number of OT-I cells, this 1.4% was
subtracted from the proportion of Va21Vb51 cells in the CD81 cells in
experimental mice and the difference was multiplied with the proportion
of CD81 T cells in the live cells and with the number of live cells. These
results are representative for two such experiments consisting of four mice
per group.242 Cross-Presentation of Self-Antigen Leads to Deletion of CD81 Cells
were recovered from the lymphatic tissues of B6®RIP–
mOVA.bm1 mice than from nontransgenic B6®bm1 mice
(Fig. 3). These data suggest that OT-I cells were deleted af-
ter recognizing exogenously processed OVA on bone mar-
row–derived APC in the draining lymph nodes of OVA-
expressing tissue.
Deletion of Constitutively Produced OT-I Cells in the Periph-
ery of RIP–mOVA Mice.  The adoptive transfer of 5 3
106 OT-I cells contrasts with the normal situation where
small numbers of newly matured cells enter the periphery
from the thymus each day. We reasoned that diabetes may
have occurred because the normal tolerogenic mechanisms
were unable to cope with such a large number of injected
T cells.
To create a more physiological situation where OVA-
specific CD81 T cells would be generated continuously in
the thymus, RIP–mOVA mice were manipulated to ensure
that OVA could not be expressed in this compartment. This
was achieved by thymectomizing RIP–mOVA mice and
then grafting them with a nontransgenic B6 thymus. Such
mice were then lethally irradiated and reconstituted with
bone marrow from OT-I mice, and designated thymus-
grafted RIP–mOVA mice (TG-RIP mice). This approach
has been successfully used to exclude the effect of aberrant
thymic antigen expression in other models (10, 14).
In contrast with the RIP–mOVA mice given large num-
bers of OT-I cells, which became diabetic within 9 d, only
1 of 12 TG-RIP mice developed the disease when followed
for .116 d. Analysis of the thymus grafts 4 mo after im-
plantation showed that OT-I cells (CD81CD42Va21 cells)
were able to mature in TG-RIP mice (Fig. 4). The propor-
tion of mature OT-I cells in the thymus was equivalent to
that of nontransgenic controls (Fig. 4, A and D), supporting
the view that the thymic deletion reported earlier for the
double-transgenic mice (27) was the result of aberrant thy-
mic expression of mOVA.
Because OT-I cells matured in the thymus of TG-RIP
mice, we could examine their fate after release into the pe-
ripheral immune system. Flow cytometric analysis of the
lymph node populations of TG-RIP mice showed a signif-
icant reduction in the proportion of these cells relative to
that seen in TG-nontransgenic mice (4.9 6 2.4% versus
25.1 6 8.2%, n 5 8) (Fig. 4, C and F). Calculation of the
total number of OT-I cells in the spleen and lymph node
populations indicated that there was approximately a five-
fold reduction of these cells in TG-RIP mice (2.28 6 1.21 3
106 versus 12.06 6 2.10 3 106; n 5 8). The remaining
OT-I cells in TG-RIP mice proliferated in vivo after re-
stimulation with antigen, demonstrating that they were not
anergic (data not shown). These data strongly suggest that
OVA-specific CD81 T cells were lost and probably deleted
once they entered the periphery.
Consistent with an active deletional process occurring in
these mice, OT-I cells from the peripheral lymphatic tis-
sues of TG-RIP mice expressed elevated levels of the acti-
vation marker CD69 (Fig. 5, A–C) and decreased levels of
L-selectin (Fig. 5, D–F) relative to that seen in TG-non-
transgenic control mice. The proportion of activated OT-I
cells was even higher in the lymph nodes draining OVA-
expressing tissues (Fig. 5, C and F), suggesting that activa-
tion of OT-I cells in TG-RIP mice also occurred in these
draining lymph nodes, presumably by the same cross-pre-
sentation mechanism that activates adoptively transferred
OT-I cells.
Figure 4. Peripheral deletion of OT-I cells that mature in the thymus
of TG-RIP mice. Thymus grafts from TG-littermate mice (A and B) and
TG-RIP mice (D and E) were analyzed for CD41, CD81, and Va21
cells by flow cytometry 16 wk after bone marrow reconstitution. Expres-
sion of Va2 by CD42CD81 cells is shown in the histograms B and E. LN
cells of the same transgenic (C) and nontransgenic (F) mice were stained
for CD81 and Va21 expression. The same staining conditions for Va2
were used for thymus and LN cells. The data shown here is representative
for eight pairs of manipulated mice investigated.
Figure 5. Analysis of the activation status of OT-I cells in TG-RIP
mice. Expression of CD69 (A–C) and L-selectin (D–F) by Va21 lym-
phocytes from the peripheral LN of TG-nontransgenic mice (A and D)
and the peripheral (B and E) and renal (C and F) LN of TG-RIP mice.243 Kurts et al.
To determine the fate of those few activated OT-I cells
remaining in the periphery of TG-RIP mice, the thymus
grafts were removed 3 mo after implantation to stop further
T cell production. The proportion of OT-I cells was then
examined in the blood at various later timepoints. This re-
vealed a continuous decline in the proportion of OT-I cells
in TG-RIP mice (Fig. 6), consistent with the idea that a
continuous deletion process was in operation. These few
remaining cells were also able to proliferate upon restimu-
lation with antigen in vivo (data not shown).
Discussion
There are now numerous reports showing that cross-
presentation of exogenous antigen can prime class I–restricted
CTL responses (33). It has also been shown to induce toler-
ance in the thymus (23). Here, we show that cross-presenta-
tion can induce peripheral tolerance that appears to operate
via a deletional process.
Although our data strongly suggest that OT-I cells were
deleted in TG-RIP mice, an alternative possibility is that
these cells had relocated to extralymphoid sites. However,
because few OT-I cells were seen in nonlymphatic tissues,
apart from small numbers of cells in the pancreatic islets
(data not shown), this possibility seems remote. It should be
emphasized that the mild islet infiltration observed is un-
likely to account for the loss of z107 cells from the second-
ary lymphoid organs of the TG-RIP mice.
Deletion has been reported as a likely mechanism of ex-
trathymic tolerance for several introduced antigens, includ-
ing superantigens (34, 35), viruses (36), soluble peptides
(37, 38), and protein (39), and for some self-antigens in
transgenic models (8, 14, 16, 40). The general belief is that
this form of tolerance results from exhaustive differentia-
tion (34). T cells are stimulated so extensively by antigen
that they proceed to end-stage effectors with limited
lifespan. Such a mechanism is consistent with the observed
activation and proliferation that precedes deletion in the
RIP–mOVA model.
Our findings provide a pathway whereby CD81 T cells
can be tolerized to self-antigens expressed in tissues outside the
normal recirculation pathway for naive T cells. As long as the
antigen can gain access to the exogenous cross-presentation
pathway, host CD81 T cells should be stimulated to die
eventually. Thus, as newly derived autoreactive CD81 T cells
enter the peripheral pool, they will encounter their autoan-
tigen on the cross-presenting APC in lymph nodes that drain
the appropriate tissues. As a result, activation will follow
and lead to deletion, thus limiting the accumulation of ig-
norant autoreactive cells in secondary lymphoid compart-
ments. This model is at odds with the previously reported
induction of diabetes in virus-primed transgenic mice ex-
pressing viral antigens in the islet b cells (3, 4), which sug-
gests that ignorant naive CD81 T cells remained in the pe-
ripheral circulation. However, the type and concentration
of the antigen and the affinity of the TCR in the respond-
ing T cell population are likely to affect the efficacy of cross-
presentation leading to deletion. In support of this conclu-
sion, we have preliminary evidence using newly generated
transgenic lines that the level of antigen expressed affects the
extent of cross-presentation (our unpublished observations).
In addition, data obtained using transgenic mice expressing
hemagglutinin (HA) under the control of the rat insulin
promoter (RIP–HA mice), support the idea that antigens
expressed in the islets are not always ignored but can acti-
vate CD81 T cells leading to tolerance induction. RIP–HA
mice crossed to TCR transgenic mice, which produced large
numbers of class I–restricted HA-specific T cells, became
diabetic (41), indicating that HA-specific CD81 T cells en-
tered the periphery of RIP–HA mice, where they were ac-
tivated by islet antigens, perhaps by cross-presentation.
Despite this observation, RIP–HA single-transgenic mice
showed HA-specific CTL tolerance (11), suggesting that the
activation process seen in double-transgenic mice may lead
to tolerance induction when the precursor frequency is
low, as in a normal T cell repertoire.
It is not clear why this form of priming should lead to
loss of activated cells when most other described cases of
cross-priming result in immunization. Perhaps it relates to
the continuous presence of the priming antigen, which pro-
vides repeated stimuli to the responding population to the
point of exhaustion. Alternatively, because there is specific
tolerance to OVA in the CD41 T cell compartment in our
model (our unpublished observations), deletion of CD81
cells may relate to a lack of CD41 T cell help, which ap-
pears to be necessary for the induction of some CD81 T cell
responses (42–44). Thus, when CD81 T cells were con-
fronted with antigen in the absence of CD41 T cells, only a
transient response followed after which all the antigen-spe-
cific T cells died (45).
Figure 6. Disappearance of OT-I cells in TG-RIP mice after removal
of their thymus graft. Thymus graft was removed from TG-RIP mice and
TG-nontransgenic controls 3 mo after implantation. The proportion of
CD81 peripheral blood cells that were Va21Vb51 was then determined
by flow cytometry on days 2, 11, 18, and 35 after thymectomy. The pro-
portion found at day 2 after removal of the thymus grafts was considered
100% in this particular mouse, and the following values were given as a
percent of this starting value. TG-RIP, not operated (s); TG-RIP, thy-
mus graft removed (,); TG-RIP, thymus graft and left kidney removed
(n); TG-nontransgenic littermate, not operated (h); TG-nontransgenic
littermate, thymus graft removed (e).244 Cross-Presentation of Self-Antigen Leads to Deletion of CD81 Cells
Deletion of OT-I cells in TG-RIP mice is consistent
with a model in which newly matured OT-I cells enter the
periphery of RIP–mOVA mice, recirculate until they come
into contact with antigen in the draining lymph nodes of
OVA-expressing tissues, and are then activated and deleted.
Such activation-induced deletion could occur in one of two
ways: either directly as a result of activation on the bone
marrow–derived cross-presenting APC, or indirectly be-
cause only activated OT-I cells are able to recirculate
through nonlymphoid tissues where they can encounter
OVA-expressing tissues and there be deleted. The observed
deletion of OT-I cells adoptively transferred into B6®RIP–
mOVA.bm1 mice indicates that secondary encounter with
antigen on peripheral tissues is not essential for deletion to
occur. However, it is important to state that although pre-
sentation of OVA on the bone marrow–derived compart-
ment was sufficient to lead to deletion, the additional abil-
ity to encounter antigen on peripheral tissue may enhance
deletion. This will be examined in future studies.
Our results provide evidence for an extrathymic mecha-
nism capable of inducing the loss of CD81 T cell respond-
ing to self-antigens expressed in tissues outside the lym-
phoid compartment. Because such tissues are normally not
directly accessible to naive CD81 T cells, the absence of
this deletion mechanism would allow accumulation of
naive autoreactive CD81 T cells. These could be primed
to effector CTL with wider recirculation pathways after a
strong environmental stimulus, thus leading to autoimmu-
nity. We speculate that the continual activation and dele-
tion of small numbers of autoreactive CD81 T cells by
cross-presentation will not result in significant autoimmune
damage.
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